417 related articles for article (PubMed ID: 19339060)
1. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Fühlhuber V; Bick S; Kirsten A; Hahn A; Gerriets T; Tschernatsch M; Kaps M; Preissner KT; Blaes F; Altenkämper S
J Neuroimmunol; 2009 May; 210(1-2):87-91. PubMed ID: 19339060
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Hoefgen ER; Swan JA; Colliver JA
Cytokine; 2008 Oct; 44(1):26-32. PubMed ID: 18675552
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis.
Piazza F; DiFrancesco JC; Fusco ML; Corti D; Pirovano L; Frigeni B; Mattavelli L; Andreoni S; Frigo M; Ferrarese C; Tredici G; Cavaletti G
J Neuroimmunol; 2010 Mar; 220(1-2):104-7. PubMed ID: 20149932
[TBL] [Abstract][Full Text] [Related]
4. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Colliver JA; Ness JM; Ransohoff RM
J Neuroinflammation; 2013 Jan; 10():10. PubMed ID: 23324534
[TBL] [Abstract][Full Text] [Related]
5. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
Raffaghello L; Fuhlhuber V; Bianchi G; Conte M; Blaes F; Gambini C; Pistoia V
J Leukoc Biol; 2013 Jul; 94(1):183-91. PubMed ID: 23610147
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies in childhood opsoclonus-myoclonus syndrome.
Blaes F; Pike MG; Lang B
J Neuroimmunol; 2008 Sep; 201-202():221-6. PubMed ID: 18687475
[TBL] [Abstract][Full Text] [Related]
7. New autoantibodies in pediatric opsoclonus myoclonus syndrome.
Kirsten A; Beck S; Fühlhuber V; Kaps M; Kreutz T; Korfei M; Schmitt S; Preissner KT; Blaes F
Ann N Y Acad Sci; 2007 Sep; 1110():256-60. PubMed ID: 17911440
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus.
Hopia L; Thangarajh M; Khademi M; Laveskog A; Wallström E; Svenungsson E; Andersson M
Scand J Rheumatol; 2011; 40(5):363-72. PubMed ID: 21585290
[TBL] [Abstract][Full Text] [Related]
9. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis.
Ragheb S; Lisak R; Lewis R; Van Stavern G; Gonzales F; Simon K
Arch Neurol; 2008 Oct; 65(10):1358-62. PubMed ID: 18852352
[TBL] [Abstract][Full Text] [Related]
10. Serum BAFF and APRIL levels in patients with PBC.
Migita K; Ilyassova B; Kovzel EF; Nersesov A; Abiru S; Maeda Y; Komori A; Ito M; Yano K; Yatsuhashi H; Shimoda S; Ishibashi H; Nakamura M
Clin Immunol; 2010 Feb; 134(2):217-25. PubMed ID: 19840904
[TBL] [Abstract][Full Text] [Related]
11. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS).
Krasenbrink I; Fühlhuber V; Juhasz-Boess I; Stolz E; Hahn A; Kaps M; Hero B; Blaes F
Neuropediatrics; 2007 Jun; 38(3):114-6. PubMed ID: 17985258
[TBL] [Abstract][Full Text] [Related]
12. IgG subclass distribution of autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Beck S; Fühlhuber V; Krasenbrink I; Tschernatsch M; Kneifel N; Kirsten A; Jaeger C; Kaps M; Preissner KT; Lang B; Rostasy K; Blaes F
J Neuroimmunol; 2007 Apr; 185(1-2):145-9. PubMed ID: 17324472
[TBL] [Abstract][Full Text] [Related]
13. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
[TBL] [Abstract][Full Text] [Related]
14. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
Pranzatelli MR; Tate ED; McGee NR; Ransohoff RM
Cytokine; 2013 Oct; 64(1):331-6. PubMed ID: 23764550
[TBL] [Abstract][Full Text] [Related]
15. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF.
Matsushita T; Fujimoto M; Hasegawa M; Tanaka C; Kumada S; Ogawa F; Takehara K; Sato S
J Rheumatol; 2007 Oct; 34(10):2056-62. PubMed ID: 17896803
[TBL] [Abstract][Full Text] [Related]
17. Age-related changes in BAFF and APRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody deficiency.
Jin R; Kaneko H; Suzuki H; Arai T; Teramoto T; Fukao T; Kondo N
Int J Mol Med; 2008 Feb; 21(2):233-8. PubMed ID: 18204790
[TBL] [Abstract][Full Text] [Related]
18. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma.
Raffaghello L; Conte M; De Grandis E; Pistoia V
Eur J Paediatr Neurol; 2009 May; 13(3):219-23. PubMed ID: 18571942
[TBL] [Abstract][Full Text] [Related]
19. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome.
Korfei M; Fühlhuber V; Schmidt-Wöll T; Kaps M; Preissner KT; Blaes F
J Neuroimmunol; 2005 Dec; 170(1-2):150-7. PubMed ID: 16203043
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis.
Matsushita T; Fujimoto M; Echigo T; Matsushita Y; Shimada Y; Hasegawa M; Takehara K; Sato S
Exp Dermatol; 2008 Mar; 17(3):197-202. PubMed ID: 17979975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
